Related Experiment Video

Updated: May 9, 2026

Quantification, Viability Assessment, and Visualization Strategies for Acinetobacter Biofilms
07:41

Quantification, Viability Assessment, and Visualization Strategies for Acinetobacter Biofilms

Published on: August 4, 2023

Prognostic differences between VAP from Acinetobacter baumanii and VAP from other microorganisms

Marianna Di Bonito1, Simona Caiazzo, Marta Iannazzone

  • 1Department of Anesthesia and Intensive Care, Federico II University, Napoli, Italy.

Translational Medicine @ Unisa
|August 2, 2013
PubMed

Insights

This study compared outcomes for critical patients with ventilator-associated pneumonia (VAP) caused by Acinetobacter baumanii versus other microbes. No significant differences in mortality or treatment success were found between groups, suggesting similar VAP management approaches may apply.

Area of Science:

  • Infectious Diseases
  • Critical Care Medicine
  • Microbiology

Background:

  • Nosocomial pneumonia poses significant risks to hospital patient mortality and morbidity.
  • Acinetobacter baumanii, a multidrug-resistant organism, frequently causes Ventilator-Associated Pneumonia (VAP).
  • Colistin is often reserved as a last-resort treatment for Acinetobacter baumanii infections.

Purpose of the Study:

  • To compare clinical outcomes of VAP caused by Acinetobacter baumanii against VAP from other microorganisms in critically ill patients.
  • To evaluate differences in comorbidity, prognostic scores, mortality rates, and eradication frequencies between the two VAP etiological groups.
  • To assess the safety profile of Colistin in the context of Acinetobacter baumanii VAP treatment.

Main Methods:

  • Retrospective study design.
  • Inclusion of critical patients diagnosed with VAP.
  • Comparison of patient groups based on the causative microorganism (Acinetobacter baumanii vs. others).
  • Analysis of clinical data including comorbidities, prognostic scores, mortality, and microbiological eradication.

Main Results:

  • No statistically significant differences were observed in comorbidity burden between the Acinetobacter baumanii and other microorganism VAP groups.
  • Prognostic scores, mortality rates, and frequency of microbial eradication did not significantly differ between the study groups.
  • The safety of Colistin as a therapeutic agent was evaluated, though specific outcomes related to its safety were noted.

Conclusions:

  • Ventilator-Associated Pneumonia caused by Acinetobacter baumanii in critical patients may have similar clinical outcomes to VAP from other pathogens.
  • The findings suggest that established VAP management strategies might be applicable regardless of the causative agent, including Acinetobacter baumanii.
  • Further research into Colistin's safety and efficacy in treating Acinetobacter baumanii VAP is warranted.
Keywords:
Acinetobacter baumaniiColistinVAP

More Related Videos

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia04:32

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia

Published on: June 28, 2018

Related Concept Videos

Automated Microbial Diagnostics01:24

Automated Microbial Diagnostics

Automated diagnostic analyzers have transformed clinical microbiology by providing rapid and reliable methods for pathogen identification and antibiotic susceptibility testing. Among these systems, the Vitek 2 is widely used because it automates the traditionally labor-intensive processes of microbial identification (ID) and antibiotic susceptibility testing (AST), delivering standardized and timely results that are essential for effective patient care.Microbial Identification with ID CardsThe...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...